Ubs Group Ag Histogen Inc. Transaction History

Ubs Group Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.39 - $0.88 $34 - $78	89 New	89 $0
Q1 2023 May 12, 2023	BUY	$0.85 - $1.41 $1,541 - $2,557	1,814 Added 40.07%	6,341 $7,000
Q4 2022 Feb 08, 2023	SELL	$0.79 - $1.49 $624 - $1,178	-791 Reduced 14.87%	4,527 $3,000
Q3 2022 Nov 10, 2022	BUY	$1.32 - $3.76 $7,019 - $19,995	5,318 New	5,318 $7,000

Ticker HSTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,497,450
Market Cap $549K
Description
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.